Selekta Rus

History

2015: The Rusnano portfolio company "Selekta (RUS)" put the equipment for production of synthetic vaccinal particles into operation

"Selekta (RUS)" (Khimki), subsidiary company of a biotechnology startup Selecta Biosciences, Inc. (Watertown, the USA), completed in the fall of 2015 installation and put into operation the unique equipment on production of synthetic vaccinal particles (SVP™) for development and further clinical trials of a new class of immunomodulatory nanomedicines. The equipment is developed by the special order "Selekta (RUS)" on the basis of unique prototypes of the company and standard component parts.

"Successful start of this equipment — an important stage in implementation of our plans. Installation will accelerate development of the innovation products and will help to confirm quicker the importance of use of synthetic vaccinal particles in one of the most promising approaches in cancer therapy — immuno-oncology" — the CEO of Selekta (RUS) company, Candidate of Biology Dmitry Ovchinnikov is sure.

The installed equipment allows to synthesize batches of vaccinal particles both for research activity in vitro, and for industrial production of medicines. In the latter case installation does not require any completions and is placed on the licensed pharmaceutical production. System implementation will allow to scale easily SVP™ production process for the different projects "Selekta (RUS)" and, including, platforms for treatment of the separate types of cancer associated with a virus of papilloma of the person (cervical cancer, a neck and the head). This platform aktivitizirut the cages of the immune system known as cytotoxic T-lymphocytes (TsTL), against the cancer cells transformed by a virus of papilloma of the person. The project on treatment of the specified types of oncological diseases got support of Skolkovo Foundation in the form of a grant in the amount of 150 million rubles on continuation of development of therapeutic vaccine and its output from clinical trial, preclinical on an early stage.

Earlier this year company Selecta Biosciences, Inc. announced the beginning of cooperation with Genethone company — the SVP™ platform will be used in gene therapy of the company for protection of virus carriers against action of antibodies and other undesirable immune reactions.

In September, 2015 Selecta Biosciences, Inc. completed a round of financing of series E with an amount of $38 million. Funds will be allocated for development of several candidates for a role antigen - specific immunotherapeutic products on the basis of the SVP™ platform. Efforts of staff of the company will be focused on the program of clinical trials of the leading candidate product SEL-212 which is developed as the first not immunogene biotherapy for treatment of gout.